Ignite Creation Date:
2024-05-06 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05319873
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-03-18
Brief Title:
Ribociclib Tucatinib and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Organization Data
Organization:
Jonsson Comprehensive Cancer Center
Class:
OTHER
Study ID:
21-001819
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Novartis | INDUSTRY |
| Seagen Inc | INDUSTRY |